AF
SPRO icon

Allworth Financial’s Spero Therapeutics SPRO Stock Holding History

Allworth Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-600
Closed -$840 – 3827
2024
Q2 		$840 Hold
600
– – ﹤0.01% 3228
2024
Q1 		$1.03K Hold
600
– – ﹤0.01% 3068
2023
Q4 		$882 Hold
600
– – ﹤0.01% 2988
2023
Q3 		$726 Hold
600
– – ﹤0.01% 2945
2023
Q2 		$870 Hold
600
– – ﹤0.01% 2774
2023
Q1 		$870 Hold
600
– – ﹤0.01% 2722
2022
Q4 		$1.04K Hold
600
– – ﹤0.01% 2461
2022
Q3 		$1K Buy
600
+498
+488% +$495 ﹤0.01% 2501
2022
Q2 		$0 Buy
+102
New +$297 ﹤0.01% 2783

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Allworth Financial's SPRO Position: Q3 2024 in Review

Allworth Financial sold out of Spero Therapeutics (SPRO) in Q3 2024, closing a stake of 600 shares — an estimated $840 sold.

Allworth Financial first reported a position in SPRO in Q2 2022 and held it in 9 quarters. The position peaked at $1.04K in Q4 2022. 46 funds tracked by Wall St. Rank hold SPRO as of Q3 2024.

  • Allworth Financial reported no remaining Spero Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Allworth Financial sold 600 Spero Therapeutics shares in Q3 2024, an estimated $840.
  • Allworth Financial first reported a position in Spero Therapeutics in Q2 2022 and held it in 9 quarters.
  • Allworth Financial's Spero Therapeutics position peaked at $1.04K in Q4 2022.
  • 46 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2024.

Based on Allworth Financial's 13F filing for Q3 2024, filed 23 Oct 2024.